reports
QNB Corp. Declares Q1 2026 Dividend
QNB Corp. Declares Q1 2026 Dividend Quakertown, PA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of QNB Corp. (OTCQX: QNBC), parent company of QNB Bank, at a regular meeting on February 24, declared a quarterly cash dividend of $0.39 per share. The cash dividend is payable on March 27, 2026, to shareholders of record March 13, 2026. QNB Corp. offers commercial and retail banking services through its twelve banking offices, which are operated by its subsidiary, QNB Bank, in Bucks, Montgomery, and Lehigh Counties. QNB Corp.’s stock is traded in the over-the-counter QX market...
Vera Therapeutics to Participate at Upcoming Investor Conferences
Vera Therapeutics to Participate at Upcoming Investor Conferences BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences. Investor Conference Details: TD Cowen 46th Annual Health Care ConferenceFormat: Fireside chat and 1x1 investor meetings Webcast: Date: ...
QNB Corp. and The Victory Bancorp, Inc. Announce Shareholder Approvals...
QNB Corp. and The Victory Bancorp, Inc. Announce Shareholder Approvals Received for Merger Quakertown, PA and Limerick, PA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- QNB Corp. ("QNB" or the "Company") (OTCQX: QNBC), the holding company for QNB Bank, and The Victory Bancorp, Inc. ("Victory") (OTCQX: VTYB), the holding company for The Victory Bank, today jointly announced that the shareholders of both QNB and Victory have voted to approve their previously announced merger transaction (the “Merger”). The transaction, initially announced on September 23, 2025, is expected to close during the second q...
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rul...
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on February 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 11,500 shares of Class A common stock and restricted stock units (RSUs) underlying 5,750 shares of Class A common stock to two (2) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan...
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Comme...
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Matt Skelton to Chief Commercial Officer, effective immediately. Mr. Skelton joined Vera Therapeutics over a year ago as the Executive Vice President, Commercial. “We are pleased to welcome Matt to the executive team as w...
QNB Corp. Reports Earnings for Fourth Quarter 2025
QNB Corp. Reports Earnings for Fourth Quarter 2025 QUAKERTOWN, Pa., Jan. 27, 2026 (GLOBE NEWSWIRE) -- QNB Corp. (the “Company” or “QNB”) (OTCQX: QNBC), the parent company of QNB Bank (the “Bank”), reported net income for the fourth quarter of 2025 of $3,981,000 or $1.06 per share on a diluted basis. This compares to net income of $3,051,000, or $0.83 per share on a diluted basis, for the same period in 2024. For the twelve months ended December 31, 2025, QNB reported net income of $14,090,000, or $3.78 per share on a diluted basis. This compares to net income of $11,448,000, or $3.12 per ...
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rul...
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on January 5, 2026, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 228,750 shares of Class A common stock and restricted stock units (RSUs) underlying 116,000 shares of Class A common stock to eighteen (18) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan...
Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Health...
Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company’s management team will present at the 44th Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 12-15, 2026. The management team will also participate in one-on-one investo...
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biolog...
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN. BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments fo...
Randall E. Stauffer Appointed to QNB Bank Board of Directors Effective...
Randall E. Stauffer Appointed to QNB Bank Board of Directors Effective January 1, 2026 Quakertown, PA, Dec. 30, 2025 (GLOBE NEWSWIRE) -- QNB Bank, a subsidiary of QNB Corp. (OTCQX: QNBC), is pleased to announce that Randall E. Stauffer has been appointed to the Board of Directors, as a Class II Director, effective January 1, 2026. Mr. Stauffer has not yet been appointed to any Board committees. Mr. Stauffer currently serves as Vice President of Sales and is a fifth-generation co-owner of Stauffer Glove & Safety, a nationwide distributor of personal protective equipment. The company ope...
- Wedbush Research
TSLA TESLA INC
NVDA NVIDIA CORPORATION
GOOGL ALPHABET INC. CLASS A
ROKU ROKU INC. CLASS A
MSFT MICROSOFT CORPORATION
DNLI DENALI THERAPEUTICS INC
LYFT LYFT
UBER UBER TECHNOLOGIES INC.
PLTR PALANTIR TECHNOLOGIES
VERA VERA THERAPEUTICS INC
PL PLANET LABS PBC
TYRA TYRA BIOSCIENCES INC
CGON CG ONCOLOGY INC
BBOT BRIDGEBIO ONCOLOGY THERAPEUTICS INC
- Laura Chico
- Thomas Yip
Vera Therapeutics Announces Pricing of Public Offering of Class A Comm...
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock BRISBANE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an underwritten public offering of 6,138,108 shares of its Class A common stock at a price to the public of $42.50 per share. The gross proceeds to Vera Therapeutics from the offering, before deducting underwriting discounts ...
Vera Therapeutics Announces Proposed Public Offering of Class A Common...
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock BRISBANE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced its plans to commence a public offering, subject to market and other conditions, to issue and sell $200.0 million of shares of its Class A common stock. All of the shares are being offered by Vera Therapeutics. In connection with the proposed...
- Jonathan Moreland
ALLE ALLEGION PLC
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
TPC TUTOR PERINI CORPORATION
SHBI SHORE BANCSHARES INC.
RPD RAPID7 INC.
NWBI NORTHWEST BANCSHARES INC.
HOO HERBALIFE NUTRITION LTD.
CALX CALIX NETWORKS
UTI UNIVERSAL TECHNICAL INSTITUTE INC.
AP AMPCO-PITTSBURGH
GBLI GLOBAL INDEMNITY PLC
MSBI MIDLAND STATES BANCORP
INSE INSPIRED ENTERTAINMENT
WMG WARNER MUSIC GROUP CORP.
PMTS CPI CARD GROUP
BHC BAUSCH HEALTH COMPANIES INC.
VRCA VERRICA PHARMACEUTICALS
ESTC ELASTIC N.V.
ENR EDGEWELL PERSONAL CARE COMPANY
SELF SELF STORAGE GROUP
TBTC INC.
VLA TABLE TRAC INC.
ONEW ARBOR METALS
ABCL ONEWATER MARINE
ALIT ABCELLERA BIOLOGICS
BMEA ALIGHT
PBBK INC. / DELAWARE
NRDY BIOMEA FUSION
OWL INC.
ENOV PB BANKSHARES
QDEL INC.
J NERDY INC.
MAIA BLUE OWL CAPITAL INC
SMRT ENOVIS CORPORATION
FISV QUIDEL CORP
PODC JACOBS SOLUTIONS INC.
GAM MAIA BIOTECHNOLOGY INC
NUTX SMARTRENT INC
BAER FISERV
TENX INC.
SGI COURTSIDE GROUP INC.
AFCG GENERAL DE ALQUILER DE MAQUINARIA
DSM NUTEX HEALTH INC
XELB WILDFIRE NEW PUBCO
ANNX INC.
KTTA TENAX THERAPEUTICS INC.
SOMNIGROUP INTERNATIONAL INC.
AFC GAMMA
INC.
DREYFUS STRATEGIC MUNICIPAL BOND FUND
INC.
XCEL BRANDS INC.
ANNEXIN PHARMACEUTICALS AB (PUBL)
PASITHEA THERAPEUTICS CORP
Universal Technical Institute Inc: 1 director
A director at Universal Technical Institute Inc bought 547,066 shares at 25.011USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the l...
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rul...
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on December 2, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 42,000 shares of Class A common stock and restricted stock units (RSUs) underlying 21,000 shares of Class A common stock to seven (7) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). Th...
- Jonathan Moreland
Vistra Corp: 1 director
A director at Vistra Corp sold 8,219 shares at 173.350USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers t...
Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of James R. Meyers, an accomplished biopharmaceutical executive with over three decades of commercial leadership experience to Vera Therapeutics’ Board of Directors. "We are thrilled to welcome Jim to our Board of...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.